Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib During and Following Autologous Stem Cell Transplantation in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT02443077Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2016
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of ibrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by National Cancer Institute. Started Oct 2016; status: active, not recruiting.
02
Drugs
ibrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02443077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02443077.